KA vs. SNGX, TBIO, EDSA, APLM, COCP, ITRM, CPIX, BIOR, FBRX, and MEIP
Should you be buying Kineta stock or one of its competitors? The main competitors of Kineta include Soligenix (SNGX), Telesis Bio (TBIO), Edesa Biotech (EDSA), Apollomics (APLM), Cocrystal Pharma (COCP), Iterum Therapeutics (ITRM), Cumberland Pharmaceuticals (CPIX), Biora Therapeutics (BIOR), Forte Biosciences (FBRX), and MEI Pharma (MEIP). These companies are all part of the "medical" sector.
Soligenix (NASDAQ:SNGX) and Kineta (NASDAQ:KA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, community ranking, dividends, valuation and analyst recommendations.
Soligenix received 275 more outperform votes than Kineta when rated by MarketBeat users. However, 100.00% of users gave Kineta an outperform vote while only 72.97% of users gave Soligenix an outperform vote.
Kineta has a net margin of 0.00% compared to Kineta's net margin of -1,025.66%. Kineta's return on equity of -198.36% beat Soligenix's return on equity.
3.6% of Soligenix shares are owned by institutional investors. Comparatively, 30.3% of Kineta shares are owned by institutional investors. 1.4% of Soligenix shares are owned by company insiders. Comparatively, 23.7% of Kineta shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Soligenix presently has a consensus price target of $3.00, suggesting a potential upside of 729.88%. Kineta has a consensus price target of $8.00, suggesting a potential upside of 1,605.76%. Given Soligenix's higher probable upside, analysts plainly believe Kineta is more favorable than Soligenix.
In the previous week, Soligenix had 3 more articles in the media than Kineta. MarketBeat recorded 6 mentions for Soligenix and 3 mentions for Kineta. Soligenix's average media sentiment score of 1.87 beat Kineta's score of 0.68 indicating that Kineta is being referred to more favorably in the news media.
Soligenix has higher earnings, but lower revenue than Kineta. Soligenix is trading at a lower price-to-earnings ratio than Kineta, indicating that it is currently the more affordable of the two stocks.
Soligenix has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, Kineta has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500.
Summary
Kineta beats Soligenix on 9 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding KA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
